Daina Graybosch

Stock Analyst at Leerink Partners

(0)
# 4738
Out of 5,358 analysts
134
Total ratings
27.38%
Success rate
-17.90%
Average return
21 Stocks
Name Action PT Current % Upside Ratings Updated
ITOS ITeos Therapeutics
Downgrades: Market Perform
47 9
10.19 -11.68% 8 May 14, 2025
AFMD Affimed
Downgrades: Market Perform
5 1
0.18 116.67% 8 May 13, 2025
TSVT 2seventy bio
Downgrades: Market Perform
9 5
n/a n/a 6 Mar 11, 2025
MRK Merck & Co
Maintains: Outperform
136 119
78.97 50.69% 19 Jan 13, 2025
LVTX LAVA Therapeutics
Downgrades: Market Perform
11 2
1.32 51.52% 6 Dec 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
3 1
0.32 212.5% 8 May 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
35 39
68.15 -42.77% 5 Mar 30, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
5 3
0.68 341.18% 10 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
20 14
0.61 2195.08% 4 Jan 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
62 10
1.6 525% 7 Jan 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
10 9
2.16 316.67% 10 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
40 38
9.96 281.53% 2 Nov 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
30 8
3.81 109.97% 4 Aug 29, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
223 224
108.54 106.38% 16 Jul 29, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
30
1.9 1478.95% 1 Jul 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
21 7
n/a n/a 4 Jun 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
18 17
1.42 1097.18% 3 May 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
25 2
n/a n/a 6 Apr 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
16 9
1.73 420.23% 4 Feb 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
5 6
n/a n/a 2 Apr 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
68
n/a n/a 1 Dec 11, 2019